Enveda Biosciences Secures $55 Million in Series B2 Funding Led by Microsoft to Advance AI-Driven Natural Product Drug Discovery

Recently, AI pharmaceutical company Enveda Biosciences announced that it has raised funds in the B2 round of financing.$55 million, to accelerate the construction of its platform and advance clinical trials for multiple drug candidates.

This round of financing is a further addition to the total B and B1 round funding of $119 million.

New investors include Microsoft, The Nature Conservancy, The Nature Conservancy, and Lingotto Investment Fund; existing investors include Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners.

As of now, the company'sTotal capital raised reached 230 million US dollarsEnveda plans to carry out a Series C financing round later this year after its candidate drug enters clinical trials.

Viswa Colluru, the founder of Enveda Biosciences, was previously a product manager at the publicly traded AI pharmaceutical company Recursion Pharmaceuticals.

Figure:Viswa Colluru

Enveda Biosciences' core philosophy is to revitalize the pharmaceutical industry's focus on natural product discovery, as many of the world's greatest drugs are derived from nature. The World Health Organization estimates that approximately 40% of modern medicines originate from natural products.

Currently, the company's database contains 38,000 medicinal plants, associated with approximately 12,000 diseases and symptoms.

The company has built an artificial intelligence platform aimed at predicting the structures of natural cellular metabolites.In addition, Enveda is building a high-throughput screening process for in vitro and in vivo testing of compounds in its chemical library. These subsequent empirical measurements help rapidly test critical drug properties, such as their functional characteristics and ultimate distribution in the body.

The platform is helping Enveda develop drugs based on inflammation and fibrosis,The two drugs of the companyExpected to begin clinical trials later this year，One is used to treat skin diseases, including eczema, and the other is used to treat inflammatory bowel disease.

Figure:Enveda Biosciences' Product Pipeline

—The End—

Recommended Reading